Related Experiment Video

Updated: Apr 15, 2026

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.4K

Optimized generation of survivin-specific cytotoxic T lymphocytes against lung cancer

Ying Li1, Juanjuan Ding1

  • 1Department of Respiratory Medicine, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China.

Molecular Medicine Reports
|April 8, 2015
PubMed

Insights

This study enhances cancer immunotherapy by optimizing dendritic cells (DCs) to target survivin. Enhanced DCs improve cytotoxic T-lymphocyte (CTL) efficiency against lung cancer, offering a promising clinical strategy.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Dendritic cell (DC)-based cancer immunotherapy targeting survivin shows promise but faces efficiency challenges.
  • Survivin-specific cytotoxic T-lymphocyte (CTL) immunotherapy requires optimization for clinical application.

Purpose of the Study:

  • To improve the efficiency of survivin-specific CTL immunotherapy against lung cancer.
  • To optimize the generation and function of dendritic cells for enhanced anti-cancer immune responses.

Main Methods:

  • Treatment of DCs with interleukin-4 (IL-4)/granulocyte-macrophage colony-stimulating factor (GM-CSF) and proinflammatory cytokines.
  • Stimulation of DCs with lipopolysaccharide (LPS).
  • Assessment of DC antigen-presenting and T-cell activation capabilities.
  • Evaluation of survivin-specific CTL cytotoxicity against lung cancer cells with varying survivin expression.

Main Results:

  • IL-4/GM-CSF and cytokine treatment significantly enhanced DC antigen presentation and capture of exogenous survivin.
  • LPS stimulation improved DC response to T-cell signals and T-cell activation.
  • Survivin-specific CTLs exhibited high cytotoxicity against survivin-expressing A549 lung cancer cells.
  • CTL cytotoxicity was reduced against A549 cells with silenced survivin expression.

Conclusions:

  • A novel method was developed to optimize the generation of survivin-specific CTLs for lung cancer treatment.
  • Enhanced DC immunotherapy holds potential for advancing clinical applications in cancer treatment.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.7K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.6K

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K